Main Uses and Therapeutic Indications

Duphalac is an osmotic laxative containing lactulose, a synthetic sugar used primarily to manage specific gastrointestinal and metabolic conditions. Its therapeutic effects are centered on altering the consistency of the stool and modifying the chemical environment of the colon.

Constipation Management

The primary use of Duphalac is the treatment of constipation. It is indicated for patients who require the restoration of a regular physiological rhythm of defecation.

Unlike stimulant laxatives, Duphalac works through osmosis. When ingested, it remains largely unabsorbed as it passes through the small intestine. Upon reaching the colon, it is broken down by resident bacteria into organic acids. This process results in:

• Water Retention: An increase in osmotic pressure that draws water into the intestinal lumen.
• Stool Softening: The increased water content softens the stool, making it easier to pass.
• Peristalsis Stimulation: The increased volume of the intestinal contents provides a physical stimulus that encourages natural bowel movements.

Portal-Systemic Encephalopathy (PSE)

Duphalac is also utilized in the management of portal-systemic encephalopathy, a neuropsychiatric condition associated with advanced liver disease. In patients with liver failure, the body struggles to filter toxins such as ammonia from the blood.

In this context, Duphalac functions as an ammonia-lowering agent through several mechanisms:

• Acidification of the Colon: The organic acids produced by the fermentation of lactulose lower the pH of the colonic contents.
• Ammonia Trapping: The acidic environment converts ammonia (NH3) into ammonium ions (NH4^+), which are not easily absorbed back into the bloodstream and are instead excreted in the stool.
• Bacterial Modulation: It promotes the growth of acidophilic bacteria that utilize ammonia, further reducing the amount available for absorption.

Additional Benefits

Beyond its primary indications, Duphalac is used in clinical settings where soft stools are considered a medical benefit. This includes:

• Post-Surgical Recovery: Assisting patients who must avoid straining during bowel movements following hemorrhoidectomies or other surgeries involving the anal or colonic region.
• Prebiotic Potential: Because it is fermented by beneficial gut flora such as Bifidobacteria and Lactobacilli, it can support a more favorable microbial balance within the digestive tract.

Regulatory References

1. NIH MedlinePlus guidance on Lactulose

Who Can and Cannot Use Duphalac? Official Eligibility Information

Official regulatory documents define specific eligibility rules, based primarily on existing medical conditions, GI integrity, and age group. These rules determine who is permitted to use the medicine and who is absolutely prohibited.

---

Populations Who Must Not Use the Medicine (Contraindications)

Duphalac is strictly contraindicated in patients with certain conditions, as listed in regulatory labeling:

• Galactosemia or rare hereditary problems of sugar intolerance (e.g., Lapp lactase deficiency), due to the presence of small amounts of unabsorbed sugars.
• Existing gastrointestinal obstruction or patients with a known risk of GI perforation.
• Known hypersensitivity to lactulose or any of the excipients.

---

Age-Specific and Conditional Eligibility

Population Group	Regulatory Status
Adults and Adolescents	Fully eligible for approved uses.
Infants and Children	Use is permitted but must be exceptional and under medical supervision only.
Pregnancy and Lactation	Use is permitted, as systemic exposure is negligible.
Renal/Hepatic Impairment	No special dosage recommendations or restrictions are documented.
Diabetes Mellitus	Use requires caution, particularly with high doses.

Older adults on long-term treatment (over 6 months) are eligible, but the labeling requires periodic control of serum electrolytes.

Interactions with other medicines and products

Duphalac's interaction profile is minimal due to its non-systemic nature, as documented in official prescribing information. Interactions are primarily pharmacodynamic and centered on the effect of the medicine on colonic chemistry and electrolyte balance.

Documented Pharmacodynamic and Chemical Interactions

Interaction Type	Interacting Substances/Classes	Description of Official Interaction Outcome
Electrolyte Balance Risk	Diuretics (e.g., Thiazides), Corticosteroids, Amphotericin B	Co-administration may increase the potential for potassium loss (hypokalemia).
Glycoside Enhancement	Cardiac Glycosides (e.g., Digoxin)	If potassium deficiency occurs due to excessive Lactulose use, the effect of cardiac glycosides may be enhanced.
pH Interference	Non-absorbable Antacids	May inhibit the desired acidification of colonic contents, potentially reducing the therapeutic efficacy.
Colonic Flora Interference	Oral Anti-infective Agents (e.g., Neomycin)	May theoretically interfere with the bacteria required to metabolize Lactulose, reducing its ability to acidify the colon.

Official Restrictions and Non-Interactions

Official regulatory documents classify these combinations as requiring caution or close monitoring. No mandatory timing separation rules are explicitly documented for co-administration with other oral medications. Due to the lack of significant systemic absorption, Lactulose is not documented in official labeling as having clinically relevant pharmacokinetic interactions involving the CYP450 enzyme system or drug transporters. No specific restrictions concerning food, alcohol, or herbal products are universally documented in the product's regulatory labels.

Microbial Fermentation and Substrate Action

The mechanism begins in the colon where the active ingredient, Lactulose, serves as a specific substrate for the resident colonic bacteria (microbiota). The fermentation process breaks the molecule down into low molecular weight organic acids, such as lactic and acetic acid, which are chemical precursors for the subsequent osmotic and physical effects.

---

Osmotic Gradient and Physical Bulk Expansion

The resulting organic acids and the unabsorbed Lactulose create a powerful hyperosmolar gradient within the colon lumen. This physical process draws and retains water from the surrounding tissues, which simultaneously achieves softening of the stool mass and a significant increase in volume (bulk).

---

Peristaltic Reflex Activation

The substantial increase in the volume and bulk of the colonic contents leads to the physical distension of the colon wall. This physical stretching triggers the peristaltic reflex, which is the bowel’s natural motor response, thereby facilitating the final physiological movement of the contents and mechanically influencing colonic motility. The mechanism is entirely localized and non-systemic, requiring 24 to 48 hours for the fermentation and osmotic effects to build up.

How Duphalac is Used: Administration Guidelines

Duphalac (Lactulose) is primarily administered via the oral route as a solution or syrup, which may be taken undiluted or mixed with water, fruit juice, or milk to improve palatability. In specific hospital settings for the management of severe hepatic encephalopathy (HE), the medicine may also be administered rectally as an enema to promote rapid laxation.

Standard Dosing and Frequency

Standard practices establish distinct dosing regimens based on the condition being addressed. The dose should be accurately measured using a calibrated device provided with the product, not a common kitchen spoon.

Indication	Adult Dosing Pattern	Frequency and Adjustment
Chronic Constipation	Starting Dose: 15 mL to 45 mL daily	Once daily, or divided into two doses. The dose is adjusted after 2-3 days to the lowest effective maintenance dose.
Hepatic Encephalopathy (HE)	Starting Dose: 30 mL to 45 mL, 3 to 4 times daily	Adjusted to produce 2 to 3 soft stools per day.

Administration Requirements and Duration

If the medicine is taken as a single daily dose, it is generally advised to take it at the same time each day, often with breakfast. The full therapeutic effect of the medicine may require two to three days of continuous use to become apparent. Adequate fluid intake (1.5 to 2 litres daily) is an integral part of the treatment protocol and is recommended. For pediatric use in constipation, administration should generally occur under medical supervision, and specific low-volume dose ranges are defined by age. If a dose is missed, it is advised to skip the missed dose and resume the regular schedule, without taking a double dose to compensate.

Evidence for Use in Chronic Functional Constipation

Lactulose was studied for conditions characterized by functional limitations, such as chronic functional constipation. The research base includes Randomized Controlled Trials (RCTs) and Systematic Reviews that primarily examined outcomes related to physical discomfort, monitoring weekly stool frequency and assessing stool consistency. Studies included adults and children with functional constipation. Studies report how symptoms evolved in the observed populations over short-term periods. Findings varied across studies when comparing Lactulose to other active comparators, and some older trials had modest sample sizes.

Evidence for Use in Hepatic Encephalopathy (HE)

Lactulose was evaluated in patients with conditions marked by functional limitations, such as Hepatic Encephalopathy (HE). The evidence is based on RCTs and Meta-analyses that research examined its role in managing acute episodes and preventing recurrence. Studies monitored outcomes related to systemic or functional imbalance, including the key biomarker, blood ammonia levels, and functional measures of mental status. Findings indicate that patterns of change in blood ammonia levels were observed in some studies. The compound was observed in studies as part of combination treatment regimens. Data are still emerging for long-term patient-reported outcomes and evidence on overall mortality is limited.

Research Landscape and Areas of Uncertainty

The research has explored the use of Lactulose in specific patient groups, including children and post-surgical patients where softer stool consistency is relevant. However, follow-up durations were limited in many core regulatory trials. Evidence quality varies across studies, and data for certain groups remain insufficient, particularly older adults with multiple complex comorbidities. Long-term effects are not fully established, and patient-reported outcomes are often insufficient. Research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Common questions about Duphalac (FAQ)

Q: What is the maximum amount of Duphalac I can take in one day?

Official regulatory prescribing information sets a clear starting dose range for chronic constipation and hepatic encephalopathy (HE). For HE, the dose may be taken up to 3 or 4 times daily to reach a specific therapeutic goal. The total daily amount is determined by a healthcare professional based on the condition being treated.

---

Q: Does Duphalac interact with alcohol or food?

According to the official product information, there are no specific restrictions documented concerning food, alcohol, or herbal products that must be avoided while taking Duphalac. Furthermore, the official labeling indicates that clinically relevant pharmacokinetic interactions are not documented.

---

Q: Is it safe to use Duphalac long-term?

The medicine's official labeling allows for use longer than six months but includes specific monitoring requirements. For adults using the medicine long-term, official guidance requires periodic control of serum electrolytes. The medicine is not intended for continuous, excessive use that leads to persistent diarrhea, as this can result in fluid and electrolyte imbalances.

How to Store and Dispose of Duphalac

Official regulatory information outlines specific requirements for storing and disposing of Duphalac (lactulose solution).

Storage and Stability

Requirement	Official Instruction
Temperature	Store at controlled room temperature, typically below 25 C or 30 C.
Handling	Do not freeze. Protect the container from direct light.
Packaging	Keep the medicine in its original container and ensure the cap is tightly closed.
Children	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Duphalac must not be disposed of in household trash or poured into wastewater. To comply with environmental and pharmaceutical waste regulations, return the medicine to a pharmacist or use an authorized drug take-back program. Disposal must be in accordance with local requirements.